Loading…
Sichuan-based pharma maker specializing in anesthesia, pain-management and psychiatric drugs, plus generics.
Sichuan-based pharma maker specializing in anesthesia, pain-management and psychiatric drugs, plus generics.
Sells anesthetic and pain drugs to hospitals, so sales follow surgery volumes. Its newer drug ciprofol, an alternative to the common anesthetic propofol, is the growth item, while older generic products face state bulk-purchasing rounds that cut their prices.
Moat: narrow (regulatory licence, process know-how). Established position in anesthesia/pain-management drugs, a specialised regulated therapeutic niche.
Headquarters: Chengdu, Sichuan, China · Founded: 1998 · Employees: 5,597
Size Haisco Pharmaceutical (002653.SZ) is a China Health Care company (Pharmaceuticals: Generic) with a market value of $10.0B, the 249th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥58.86 on 6 Nov 2026.
Performance Over six months the shares gained 0.6%, against -11.0% for the median peer and -16.4% for the China market (cap-weighted) — 4th highest of 9 in its peer set.
Growth Revenue grew 42.2% over the last twelve months (peer median -3.8%); the operating margin is 17.8% (peer median 0.5%).
Valuation It trades at 39.3× forward earnings against a peer median of 20.2× (2nd most expensive of 5).
Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +15 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 12.4 points above its cost of capital (5.7% WACC).
Next results Next results expected around 21 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.06B | CN¥4.35B | CN¥3.69B | CN¥3.32B | CN¥2.99B |
| Revenue growth | — | +18% | +11% | +11% | — |
| Gross profit | CN¥4.87B | CN¥3.02B | CN¥2.56B | CN¥2.29B | CN¥1.96B |
| EBITDA | n/a | CN¥459M | CN¥407M | CN¥529M | CN¥338M |
| Net income | CN¥1.34B | CN¥260M | CN¥395M | CN¥295M | CN¥277M |
| Free cash flow | CN¥1.11B | CN¥465M | CN¥98.2M | CN¥60.5M | -CN¥610M |
| Capital expenditure | CN¥355M | CN¥332M | CN¥441M | CN¥391M | CN¥700M |
| Total debt | CN¥2.27B | CN¥2.04B | CN¥1.99B | CN¥1.82B | CN¥2.14B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Haisco Pharmaceutical 002653.SZ | $10.0B | +1% | +42% | 18% | 39.3× | 20.5% |
| Humanwell Healthcare (Group) 600079.SS | $4.71B | +3% | -3% | 16% | 13.4× | -6.8% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | $3.47B | +2% | +3% | 19% | 19.6× | -2.2% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% |
| Hansoh Pharma 3692.HK | $26.9B | -7% | +25% | 38% | 27.5× | 8.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002653.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.9% | -9.7% | 4th highest of 9 |
| 6-month return | +0.6% | -11.0% | 4th highest of 9 |
| Distance from 52-week high | -27.2% | -40.1% | 4th highest of 9 |
| Revenue growth (TTM) | +42.2% | -3.8% | 2nd highest of 9 |
| Operating margin | 17.8% | 0.5% | 4th highest of 8 |
| Forward P/E | 39.3× | 20.2× | 2nd most expensive of 5 |
| Growth the price implies (Req g, 7 yrs) | 20.5% | 10.2% | most demanding of 4 |
| Growth delivered (Del g) | +5.7% | +1.0% | 2nd highest of 4 |
| Hurdle (Req g minus delivered) | +14.9 pp | +9.2 pp | 2nd most demanding of 4 |
| ROIC minus cost of capital | +12.4 pp | -3.5 pp | highest of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Haisco Pharmaceutical 002653.SZ | China | $10.0B | +1% | +42% | 18% | 39.3× | 20.5% | +5.7% |
| Hikma Pharmaceuticals HIK.L | United Kingdom | $4.59B | +18% | +2% | 20% | 9.9× | 1.4% | +6.8% |
| Neuren Pharmaceuticals NEU.AX | Australia | $2.04B | +83% | -68% | 20% | 39.5× | n/a | n/a |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | United States | $49.7B | +19% | -4% | 19% | 15.1× | 10.2% | +1.0% |
| Vigonvita Life Sciences 2630.HK | Hong Kong | $1.48B | -11% | +763% | -327% | n/a | n/a | n/a |
| Suzhou Ribo Life Science 6938.HK | Hong Kong | $939M | -29% | +4% | -187% | n/a | n/a | n/a |
| Realcan Pharmaceutical 002589.SZ | China | $628M | -11% | -4% | 0% | n/a | 17.7% | -23.1% |
| Tibet Duo Rui Pharmaceutical 301075.SZ | China | $552M | -45% | -6% | -34% | n/a | n/a | n/a |
| Zhejiang Shouxiangu Pharmaceutical 603896.SS | China | $398M | -22% | -10% | n/a | 25.4× | n/a | n/a |